Form 8-K

Date: May 10, 2021

AMNEAL PHARMACEUTICALS, INC.

/s/ Stephen J. Manzano

Stephen J. Manzano

Senior Vice President, General Counsel and Corporate Secretary

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 5, 2021

AMNEAL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38485

32-0546926

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

400 Crossing Blvd

Bridgewater, NJ 08807

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (908) 947-3120

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Class A Common Stock, par value $0.01 per share

AMRX

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07

Submission of Matters to a Vote of Security Holders.

The Company held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) on May 5, 2021. Each of the proposals was approved, and each of the director nominees was elected, by the vote of the stockholders at the Annual Meeting as follows:

Proposal 1: To elect the following director nominees to hold office until the 2022 Annual Meeting of Stockholders and until their respective successors are elected and qualified:


	For		Against		Abstain		Broker Non- Votes
Emily Peterson Alva		231,387,113		3,503,246		24,437		18,156,126
J. Kevin Buchi		196,515,957		35,282,932		3,115,907		18,156,126
Jeff George		202,051,430		29,805,650		3,057,716		18,156,126
John Kiely		195,800,930		36,058,602		3,055,264		18,156,126
Paul Meister		206,606,442		25,255,223		3,053,131		18,156,126
Ted Nark		211,039,400		20,820,472		3,054,924		18,156,126
Chintu Patel		234,218,682		658,505		37,609		18,156,126
Chirag Patel		234,094,799		787,783		32,214		18,156,126
Gautam Patel		231,217,092		3,586,717		110,987		18,156,126
Shlomo Yanai		234,425,336		450,144		39,316		18,156,126

Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers:

For

Against

Abstain

Broker Non-

Votes

233,858,559

881,197

175,040

18,156,126

Proposal 3: Approve an amendment to and restatement of the Amneal Pharmaceuticals, Inc. Certificate of Incorporation to remove references to the Company’s former Class B-1 common stock;

For

Against

Abstain

Broker Non-

Votes

252,305,563

248,527

516,832

Proposal 4: To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021:

For

Against

Abstain

Broker Non-

Votes

252,745,819

269,437

55,666